BioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.
